PLx Pharma Inc. Common Stock
PLXP
PLXP was delisted on the 12th of April, 2023.
29 hedge funds and large institutions have $36.1M invested in PLx Pharma Inc. Common Stock in 2015 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
4% more funds holding
Funds holding: 28 → 29 (+1)
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
18% less capital invested
Capital invested by funds: $43.9M → $36.1M (-$7.82M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSVM
Lone Star Value Management
Old Greenwich,
Connecticut
|
+$1.62M |
| 2 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$503K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$456K |
| 4 |
OPPM
Opus Point Partners Management
New York
|
+$300K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$167K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.05M |
| 2 |
TCM
Timpani Capital Management
Milwaukee,
Wisconsin
|
-$469K |
| 3 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$397K |
| 4 |
RFC
Russell Frank Company
Seattle,
Washington
|
-$105K |
| 5 |
Morgan Stanley
New York
|
-$103K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $26K | – | – | – |
|
27
UBS Group
Zurich,
Switzerland
| $25K | +$1.34K | +14 | +5% |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| $21K | +$13.2K | +138 | +155% |
|
|
BIM
29
BlackRock Investment Management
Wilmington,
Delaware
| $10K | – | – | – |
|
|
PWAM
30
Park West Asset Management
San Francisco,
California
| – | -$397K | -3,546 | Closed |
|
|
FMA
31
FNY Managed Accounts
New York
| – | -$7K | -63 | Closed |
|
32
Walleye Trading
New York
| – | -$7K | -63 | Closed |
|
PLXP Hedge Fund Activity: Q4 2015 in Review
29 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in PLx Pharma Inc. Common Stock (PLXP) for Q4 2015, worth a combined $36.1M — down 18% from $43.9M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PLXP positions and 3 closed out — a net gain of 1 holder — while 9 added to existing stakes and 9 trimmed.
The largest buyer was Lone Star Value Management, adding an estimated $1.62M. The largest seller was Alyeska Investment Group, cutting an estimated $1.05M.
- 29 institutional investors held PLx Pharma Inc. Common Stock (PLXP) as of Q4 2015, up from 28 in Q3 2015.
- Funds reported $36.1M of PLx Pharma Inc. Common Stock stock for Q4 2015, down 18% quarter-over-quarter.
- 4 funds opened new PLx Pharma Inc. Common Stock positions in Q4 2015 and 3 closed out, a net change of +1 holder.
- The largest PLx Pharma Inc. Common Stock buyer in Q4 2015 was Lone Star Value Management, an estimated $1.62M added.
- The largest PLx Pharma Inc. Common Stock seller in Q4 2015 was Alyeska Investment Group, an estimated $1.05M sold.
Based on aggregated 13F filings for Q4 2015.